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1. Introduction 
6. References and Recognition 
Background and Significance 
Most cancer chemotherapy makes patients 
sick because the drugs used are toxic to 
normal tissues as well.  If one could 
selectively sensitize a cancer cell to 
chemotherapy or radiation, patients could 
receive lower doses of the chemotherapy, 
which in turn would reduce this unwanted 
toxicity. Since many types of cancer 
chemotherapy and radiation cause DNA 
damage, one way to sensitize a cancer cell to 
therapy is by interfering with the 
mechanisms by which it repairs DNA. Work 
from the Hartman lab developed a peptide 
that binds with moderate affinity (KD of 
1μM)  to the C-terminal (BRCT)2 domain of 
breast cancer associated protein (BRCA1).1 
This protein is a critical component of DNA 
repair by homologous recombination.  
5. Future Direction 
4. Discussion 
2. Hypothesis 
The crystal structure of peptide 8.6 
(MCTIDFDEYRFRKT) bound to BRCA1 
(BRCT)2 domain shows that the side chains 
of the underlined tyrosine and threonine 
residues are close together (Fig. 1). Our 
hypothesis is that by cyclizing these 
posit ions, the peptide may become 
constrained into its bound conformation.  
We used a bis-cysteine mutant of our peptide 
MCTIDFNECRFRKC that will mimic the 
bound conformation when cyclized. A series 
of bis(bromomethyl)naphthalene linkers 
(Table 1) will be used for cyclization in order 
to vary and optimize the end-to-end distance 
of the cysteine residues.  
  
 
Synthesis of linkers (Fig. 2) 
-monitored by thin layer chromatography 
-purified through column chromatography 
-final products confirmed by 1H and 13C 
NMR.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Synthesis of peptide 8.6 (Fig. 3 A) 
-automated microwave-enhanced solid-phase 
peptide synthesis (SPPS) 
 
Deprotection of s-t-butyl and FMOC groups 
(Fig. 3 B) 
-  In DTT and ammonium bicarbonate 
Cyclization with linker (Fig. 3 C) 
-  In TCEP and ammonium carbonate 
 
Fluorescence labeling (Fig. 4 D) 
-5-FAM with DCC and HOBt 
 
 
 
 
 
The binding of the cyclic peptides with 
BRCA1 (BRCT)2 domain will be compared to 
peptide 8.6 through the use of fluorescence 
polarization. 
 
The Hartman lab is also working to increase 
binding affinity through various mutations to 
the peptide sequence.  
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Why use dibromomethylnaphthalene 
linkers? 
-  Very robust, easy to cyclize with cysteines2 
-  mRNA display compatible (can use this 
cyclization strategy for future targets) 
-  Attaching the bromomethyl groups at 
different locations of the naphthalene ring 
provides variability in size 
The 7th residue in the sequence was changed 
from aspartate to asparagine to avoid 
aspartimide formation during synthesis. 
 
Table 1. Synthesized and commercially purchased 
linkers used to cyclize 
 Methods cont.  3. Methods 
Figure 2. Synthesis of 1,4-bis(bromo)methylnaphthalene  
Thr 
Tyr 
Figure 1. Crystal Structure of bound peptide 8.6 on 
BRCA1 
Figure 3. MALDI-MS of peptide 8.6 at synthesis 
(A), deprotection (B), cyclization (C), fluorescence 
labeling (D)  
A 
B 
C 
D 
5-FAM 
Improving binding affinity through cyclization 
